![]() However, the studies differed in the period of exposure following the vaccine, which was up to 27 days in the Nordic study versus 7 days in the present study from the United States. ![]() population shows just the opposite (between 7 to 10 per 100,000 patients who received the BNT162b2 versus about 5 per 100,000 who received the mRNA1273 vaccine).īoth studies are consistent in reporting risk of myocarditis in adolescent and young adult males, and the fact that there is a higher incidence after the second dose. In the Nordic study published in JAMA Cardiology in April 2022 the incidence of myocarditis in young adolescent and adult males aged 16 to 24 was lower in those who received the BNT162b2 vaccine (4 to 7 per 100,000 vaccinated individuals) compared to the mRNA-1273 vaccine (9 to 28 per 100,000 vaccinated individuals) (1). Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |